UK Launch For R-PR's Rilutek
Rhone-Poulenc Rorer's amyotrophic lateral sclerosis treatment, Rilutek (riluzole), has been launched in the UK. Previously available only in the USA, it is approved for use, and is awaiting launch in all 14 other European Union member countries (Marketletter June 17).
Rilutek is indicated for the extension of life or the time to mechanical ventilation in patients with ALS. A Phase III clinical trial in 959 patients has shown that riluzole increased the survival rate by 35% after 18 months compared to placebo.
The data sheet for the drug notes that it should be used with care in patients with abnormal hepatic functioning or those with elevated transaminase levels. If fever occurs it may suggest neutropenia, and the drug should be stopped. More common side effects of Rilutek include asthenia, nausea, tachycardia and somnolence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze